Press Release

Medidata Wins Citeline Awards for myMedidata, the Most Comprehensive Patient Portal for Decentralized Clinical Trials, and its Holistic Digital Oversight Solution to Enable Clinical Monitoring Strategies

Medidata recognized for its exceptional innovations in life sciences, using technology to engage patients, optimize clinical trials, and accelerate the development of new therapeutics and vaccines

New York – April 11, 2022 – Medidata, a Dassault Systèmes company, is pleased to announce that it was recognized for its outstanding accomplishments in life sciences by the Citeline Awards:

  • Best Patient-Facing Technology Initiative for myMedidata, a single-destination web-based portal for patients to engage pre-trial, in-trial, and post-trial, built for patients, by patients.
  • Best Sponsor-Facing Technology Initiative for Medidata’s Digital Oversight Solution, which facilitates clinical trial data oversight and monitoring, improving timelines, cost, and quality in the execution of decentralized clinical trials (DCTs).

The Citeline Awards celebrate critical achievements across the spectrum of key R&D activities, from successes in early and late-stage research, to advances in technological tools, to innovations in trial design and execution. Medidata was presented with the awards in a ceremony held on April 7 in Boston.

 myMedidata was recognized as a powerful, intuitive, patient-centric portal. The Citeline Best Patient-facing Technology Initiative recognizes the growing role of technology in facilitating participation in clinical trials and is awarded to the product which best advances patient data collection and improves overall patient experience. myMedidata enables patients to seamlessly connect with any online device to virtually learn about, enroll in and participate in clinical trial activities. It is the industry’s single most comprehensive, integrated tool set for all aspects of clinical research. It is built on Medidata’s industry leading Rave EDC (Electronic Data Capture) system, currently in use at more clinical research sites globally than any other system.

Medidata’s Digital Oversight Solution was commended for its transformative impact on all core activities of the trial process. Medidata’s Digital Oversight Solution has a unique position in the market, unifying risk management, centralized monitoring, and a robust clinical trial management system (CTMS) on one platform. This solution makes it possible for study teams to prepare for and analyze high volumes of data, at scale and in time to take action. The technology can move teams away from delayed, reactive methodologies to proactive and predictive strategies, as well as optimize physical and virtual interactions with clinical sites.

Sastry Chilukuri, co-CEO of Medidata, said, “The patient’s interest is at the core of what we do, which is why we have worked hard to pioneer products that make clinical trials more accessible and engaging. As the first company to leverage digital health technologies for DCTs, we are proud to have received the Citeline Awards for myMedidata and Medidata’s Digital Oversight Solution. We will continue to support the movement toward trial decentralization with ever-expanding offerings, which deliver high quality data and improve the patient experience.”

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,900+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

 About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

 Contact

Tom Paolella

Senior Director, Corporate Communications & Affairs

+1-848-203-7596

thomas.paolella@3ds.com

 

Paul Oestreicher

External Communications Director

+1-917-522-4692

paul.oestreicher@3ds.com